LifeWatch AG: Biotelemetry veröffentlicht die definitive Meldung des
Zwischenergebnisses

^
EQS Group-Ad-hoc: LifeWatch AG / Schlagwort(e): Übernahmeangebot
LifeWatch AG: Biotelemetry veröffentlicht die definitive Meldung des
Zwischenergebnisses

14.06.2017 / 07:00 CET/CEST
Veröffentlichung einer Ad-hoc-Mitteilung gemäss Art. 53 KR

---------------------------------------------------------------------------

BioTelemetry veröffentlicht die definitive Meldung des Zwischenergebnisses

ZUG, Schweiz, 14. Juni 2017 - Mit der Veröffentlichung des definitiven
Zwischenergebnisses bestätigte BioTelemetry (die Anbieterin) heute, dass
rund 83 Prozent der LifeWatch-Aktien angedient wurden und erklärte das
Angebot, unter Vorbehalt der Erfüllung gewisser Angebotsbedingungen, als
zustande gekommen.

Unter Einschluss der in das Angebot angedienten LifeWatch Aktien, besteht
die Beteiligung der Anbieterin und der mit der Anbieterin in gemeinsamer
Absprache handelnden Personen am Ende der Angebotsfrist am 8. Juni 2017,
16.00 Uhr MEZ, aus insgesamt 15,425,499 Aktien, entsprechend 83 Prozent der
Stimmrechte und des Aktienkapitals von LifeWatch.

Die Nachfrist von 10 Börsentagen zur nachträglichen Annahme des Angebots
beginnt am 15. Juni 2017 und dauert voraussichtlich bis zum 28. Juni 2017,
16.00 Uhr MEZ. Vorbehältlich der Erfüllung sämtlicher Bedingungen des
Angebotsprospekts, findet der Vollzug des Kaufangebots voraussichtlich am
13. Juli 2017 statt.

Für Rückfragen:
LifeWatch AG, Andrew Moore, CFO
c/o Communicators AG , Ralph Spillmann
Mobile: +41 79 514 64 84
E-Mail: investor-relations@lifewatch.com

Zu LifeWatch AG
LifeWatch AG, mit Hauptsitz in Zug und Kotierung an der SIX Swiss Exchange
(LIFE) in der Schweiz, ist ein führender Anbieter von ferngesteuerten
diagnostischen "Digital Health" Dienstleistungen. Die Dienstleistungen von
LifeWatch liefern den Ärzten wichtige Informationen zur angemessenen
Behandlung ihrer Patienten mit dem Ziel, die Behandlung zu optimieren.
LifeWatch AG verfügt über operative Tochtergesellschaften in den USA, der
Schweiz, Israel und der Türkei und ist die Muttergesellschaft von LifeWatch
Services, Inc., LifeWatch Technologies Ltd. und LifeWatch Turkey Holding AG
(Joint Venture). LifeWatch Services, Inc. ist ein führender US-Anbieter für
Herzüberwachungsdienstleistungen. LifeWatch Technologies Ltd. in Israel ist
ein führender Hersteller von Digital-Health-Produkten. LifeWatch Salk
Hizmetlerine A.S. ist die operative Tochtergesellschaft der LifeWatch Turkey
Holding AG und Anbieter von Herzüberwachungsdienstleistungen in der Türkei.

Für weitere Informationen: siehe www.lifewatch.com.

E-Mail Alert: Um regelmässig die neusten Informationen zu LifeWatch zu
erhalten und Unterlagen anzufordern, registrieren Sie sich bitte unter
https://www.lifewatch.com/Investor-Relations/Alert-Service.html.

Zu BioTelemetry
BioTelemetry, Inc., früher als CardioNet bekannt, ist ein führendes
Unternehmen im Bereich kabelloser Medizinaltechnologie. Der Fokus liegt auf
der Bereitstellung von Gesundheitsdaten zur Verbesserung der Lebensqualität
sowie zur Reduktion der Gesundheitskosten. Das Unternehmen bietet zurzeit
Herzüberwachungs-Dienstleistungen an und produziert Geräte mit einem
primären Fokus auf die Herzüberwachung sowie zentralisierte Dienstleistungen
für Herzlaboratorien.

Für weitere Informationen: siehe www.biotelinc.com.

Cautionary Statement Regarding Forward-Looking Satements
This document includes certain forward-looking statements regarding, among
other things, statements about both, LifeWatch's and BioTelemetry's beliefs
and expectations, statements about BioTelemetry's proposed acquisition of
LifeWatch AG, including the timing and success of the tender offer and
expectations regarding the growth and success of the combined entity. These
statements may be identified by words such as "expect," "anticipate,"
"estimate," "intend," "plan," "believe," "promises", "projects," and other
words and terms of similar meaning. Such forward-looking statements are
based on current expectations and involve inherent risks and uncertainties,
including important factors that could delay, divert, or change any of these
expectations, and could cause actual outcomes and results to differ
materially from current expectations. Factors that may materially affect
such forward-looking statements include: BioTelemetry's ability to
successfully complete the tender offer for LifeWatch's shares or realize the
anticipated benefits of the transaction; and the failure of any of the
conditions to BioTelemetry's tender offer to be satisfied. For further
details and a discussion of these and other risks and uncertainties, please
see BioTelemetry's public filings with the Securities and Exchange
Commission, including the company's latest periodic reports on Form 10-K and
10-Q respectively LifeWatch's past press releases, reports and other
information posted on LifeWatch's website. Readers are cautioned not to put
undue reliance on forward-looking statements, which reflect only opinions as
of the date of this press release. BioTelemetry and LifeWatch do not
undertake, and specifically disclaim, any obligation to publicly update or
amend any forward-looking statement, whether as a result of new information,
future events, or otherwise.

OFFER RESTRICTIONS
The public tender offer described in the offer documents (the "Offer") is
not being and will not be made, directly or indirectly, in any country or
jurisdiction in which it would be considered unlawful or otherwise violate
any applicable laws or regulations, or which would require BioTelemetry or
any of its subsidiaries to change or amend the terms or conditions of the
Offer in any material way, to make an additional filing with any
governmental, regulatory or other authority or take additional action in
relation to the Offer. It is not intended to extend the Offer to any such
country or jurisdiction. Any such documents relating to the Offer must
neither be distributed in any such country or jurisdiction nor be sent into
such country or jurisdiction, and must not be used for the purpose of
soliciting the purchase of securities of LifeWatch by any person or entity
resident or incorporated in any such country or jurisdiction.

Notice to U.S. Persons Holding LifeWatch Shares
The Offer is made for the securities of a non-U.S. company. The Offer is
subject to the disclosure and procedural requirements of Switzerland, which
are different from those of the United States (the "U.S.").

According to the laws of Switzerland, LifeWatch shares tendered into the
Offer may be withdrawn after they are tendered until the expiration of the
main offer period.

BioTelemetry and any of its subsidiaries and any advisor, broker or
financial institution acting as an agent or for the account or benefit of
BioTelemetry or the Offeror may, subject to applicable Swiss securities
laws, rules and regulations, make certain purchases of, or arrangements to
purchase, LifeWatch shares from shareholders of LifeWatch who are willing to
sell their LifeWatch shares outside the Offer from time to time, including
purchases in the open market at prevailing prices or in private transactions
at negotiated prices. The Offeror will disclose promptly any information
regarding such purchases of LifeWatch shares in Switzerland through the
electronic media and/or the stock exchange and in the U.S. by means of a
press release, if and to the extent required under applicable laws, rules
and regulations in Switzerland.

It may be difficult for U.S. holders to enforce their rights and any claim
arising out of U.S. federal securities laws, since LifeWatch is located in a
non-U.S. jurisdiction, and some or all of its officers and directors may be
residents of a non-U.S. jurisdiction. U.S. holders may not be able to sue a
non-U.S. company or its officers or directors in a non-U.S. court for
violations of the U.S. securities laws. Further, it may be difficult to
compel a non-U.S. company and its affiliates to subject themselves to a U.S.
court's judgment.

The receipt of cash and stock consideration in the Offer by a U.S.
shareholder will generally be a taxable transaction for U.S. federal, state
and local income tax purposes. Each U.S. shareholder is urged to consult his
independent professional adviser immediately regarding the tax consequences
of acceptance of the Offer.

Securities may not be offered or sold in the U.S. absent registration or an
exemption from registration under the U.S. Securities Act. It is expected
that the Offer will be subject to a Tier I exemption pursuant to Rule
14d-1(c) of the U.S. Securities Exchange Act of 1934, as amended, and that
the issuance of BioTelemetry Common Stock in connection therewith will be
exempt from registration under the U.S. Securities Act of 1933, as amended,
pursuant to Rule 802 thereof.

Neither the Securities and Exchange Commission nor any securities commission
of any State of the U.S. has (a) approved or disapproved of the Offer, (b)
passed upon the merits or fairness of the Offer, or (c) passed upon the
adequacy or accuracy of the disclosure in the pre-announcement. Any
representation to the contrary is a criminal offense in the U.S.

Im Zweifelsfall gilt die englische Originalmeldung.

Zusatzmaterial zur Meldung:


Dokument: http://n.eqs.com/c/fncls.ssp?u=ACROBTKUUF
Dokumenttitel: LifeWatch AG: Biotelemetry veröffentlicht die definitive
Meldung des Zwischenergebnisses

---------------------------------------------------------------------------

Ende der Ad-hoc-Mitteilung

---------------------------------------------------------------------------

   Sprache:          Deutsch
   Unternehmen:      LifeWatch AG
                     Baarerstrasse 139
                     6300 Zug
                     Schweiz
   Telefon:          +41 41 728 67 78
   Internet:         www.lifewatch.com
   ISIN:             CH0012815459
   Valorennummer:    811189
   Börsen:           Freiverkehr in Berlin, Stuttgart; Open Market in
                     Frankfurt; SIX Swiss Exchange



   Ende der Mitteilung    EQS Group News-Service
---------------------------------------------------------------------------

582833 14.06.2017 CET/CEST

°